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Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain
and altered bowel habit, and often associates with other gastrointestinal symptoms such
as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal
symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also
frequently coexists with conditions that may also involve central sensitization processes,
such as ﬁbromyalgia, irritable bladder disorder, and chronic cough. This review examines
the evidence to date on gabapentin and pregabalin which may support further and con-
tinued research and development of the α2δ ligands in disorders characterized by visceral
hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal-
cium channel, possible mechanisms of action, pre-clinical data which supports an effect
on motor–sensory mechanisms and clinical evidence that points to potential beneﬁts in
patients with IBS will be discussed.
Keywords: α2δ ligands, gabapentin, pregabalin, irritable bowel syndrome, visceral sensitivity, central sensitization,
peripheral sensitization, motility
INTRODUCTION
ABDOMINAL PAIN AND VISCERAL HYPERSENSITIVITY
Abdominal pain and discomfort along with altered bowel habit
are integral to the diagnosis of irritable bowel syndrome (IBS).
Although disordered bowel habit can often be improved in these
patients, efﬁcacious treatment of pain, abdominal discomfort,
and associated symptoms, such as bloating, remains challeng-
ing. The identiﬁcation and development of new drugs to treat
these symptoms has been largely unsuccessful and remains prob-
lematic, probably linked to the complexity of the functional gas-
trointestinal disorders (FGIDs) in which multiple factors appear
to contribute to their equally multifarious pathophysiology. For
example, genetic predisposition, infection, and traumatic events in
early life may all predispose individuals to developing IBS, whilst
chronic stress, psychological symptoms, and maladaptive coping
mechanisms can increase the frequency and severity of symptoms
(Levy et al., 2006; Chitkara et al., 2008; Saito and Talley, 2008;
Spiller and Garsed, 2009). Pathophysiologies identiﬁed to date
include gastrointestinal dysmotility, abnormalities in the inﬂam-
matory/immune system, increased intestinal permeability, unsta-
ble or altered enteric ﬂora, psychopathology, visceral and somatic
hypersensitivity, and abnormal CNS processing (Longstreth et al.,
2006; Spiller et al., 2007). Although not all abnormalities are
present in all patients, visceral hypersensitivity which often asso-
ciates with the symptoms of pain (Posserud et al., 2007) and
bloating (Posserud et al., 2007; Agrawal et al., 2008) and which is
often exacerbated by stress, is thought bymany to be a determinant
or biological measure of IBS (Mertz et al., 1995; Bouin et al., 2002).
For example, Mertz et al. (1995) showed altered rectal perception
in almost all IBS patients in the form of either lowered sensory
thresholds, increased sensation intensity or altered viscerosomatic
referral, whilst Bouin et al. (2002) suggested that a pain threshold
of less than 40mmHg in the rectum correctly identiﬁed IBS from
non-IBS subjects. In addition, whilst only approximately half of
IBS patients appear to exhibit lowered rectal sensory thresholds to
balloon distension (Whitehead and Palsson, 1998; Posserud et al.,
2007), almost all patients (70%) show hypersensitivity elsewhere
in the gastrointestinal tract, especially in the jejunum (Francis
et al., 1995;Hammonds et al., 1998). Moreover, in the latter studies
(Francis et al., 1995; Hammonds et al., 1998) within the group as
a whole, and especially in those subjects with diarrhea, lower pain
thresholds were observed throughout the entire GI tract compared
with healthy controls.
CENTRAL SENSITIZATION
These observations of pan-gastrointestinal visceral hypersensi-
tivity and increased viscerosomatic referral, along with reported
increases in expression of extra-intestinal symptoms such as
headache, dyspareunia, heartburn, muscle pain and back pain
(Whorwell et al., 1986; Mayer and Gebhart, 1994), and presence of
ﬁbromyalgia in some patients (Whitehead et al., 2002; Almansa
et al., 2009) are consistent with a widespread aberrant central
processing of pain (central sensitization) in these patients. Fur-
ther support is provided by the observations that whilst healthy
volunteers exhibit an inhibition of the somatic nociceptor ﬂex-
ion reﬂex (R-III) to slow ramp distension of the rectum, IBS
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patients exhibit a facilitation of this reﬂex, suggesting enhanced
spinal processing in IBS (Cofﬁn et al., 2004). In addition, there are
an increasing number of studies suggesting that IBS patients may
also be hypersensitive to somatic stimuli. One such study, showed
hypersensitivity to rectal balloon distension and cutaneous ther-
mal stimulation of the hand and foot in IBS comparedwith control
subjects (Verne et al., 2001). Interestingly foot hypersensitivity was
greater than hand hypersensitivity, suggesting greater convergence
and overlap of rectal and foot afferents at common lumbosacral
levels (greater central hyperalgesia) than rectal and hand afferents
at the levels of the cervical spinal (Verne et al., 2001).
POSSIBLE SYNERGISTIC MECHANISMS
Along with the spinal (central) sensitization, other possible syner-
gisticmechanismsof visceral hypersensitivity includedisturbances
in the cognitive and emotional aspects of pain (e.g., hypervig-
ilance, somatization, catastrophizing, depression), alterations in
descending excitatory and inhibitory pathways (e.g., diffuse nox-
ious inhibitory control,DNIC),and sensitizationof afferent nerves
(e.g.,peripheral sensitizationdue to for examplemucosal insult).A
quantitative meta-analysis of functional neuroimaging studies in
IBS patients during rectal distension showed greater recruitment
of attentional (lateral prefrontal cortex), affective (ventral anterior
cingulated cortex [ACC], amygdala, dorsal pons), and homeo-
static afferent circuits (insula, dorsal ACC, thalamus) compared
with controls, with increased regional activity in the insula (INS)
and anterior midcingulate cortex (aMCC) being most commonly
reported (Labus et al., 2009). More recent studies investigating
anatomical differences in the brain between IBS and control sub-
jects have shown morphometric changes in gray matter density
predominantly in areas involved in cognition and evaluation, with
changes in other areas of the brain being generally explained
by anxiety and depression levels in the IBS patients (Seminow-
icz et al., 2010). In another study by Heymen et al. (2010), in
which DNIC was assessed in IBS compared with healthy subjects
by measuring the reduction in left hand thermal pain intensity
during counter irritation by submersion of the right hand in 12˚C
water (conditioning stimulus, CS), and controlling for the non-
speciﬁc effects on pain perception, such as distraction from the
CS, psychological symptoms, and cardiovascular reactivity, it was
shown that IBS patients demonstrate deﬁcient DNIC probably
attributed to disordered central analgesic mechanisms. This deﬁcit
has subsequently been shown to directly correlate with visceral
hypersensitivity (Piche et al., 2010). Indeed in the morphologi-
cal study described above signiﬁcant reductions in gray matter
density were observed in the periaqueductal gray, an area known
to play a major role in descending pain modulation, which was
independent of anxiety and depression (Seminowicz et al., 2010).
Other studies have shown that peripheral mucosal insults, such as
the presence of inﬂammation, injury or excess acid do not only
increase pain sensitivity at the site of injury (primary hyperalge-
sia/peripheral sensitization) but also at more remote sites in the
gastrointestinal tract (secondary hyperalgesia), via the process of
central sensitization (Anand et al., 2007; Knowles and Aziz, 2009).
One example in FGIDs, is the observation that pain thresholds to
electrical stimulation were not just reduced at the distal end of
the esophagus where acid was infused but also in the unexposed
proximal esophagus of patients with non-cardiac chest pain, with
this sensitization process being signiﬁcantly magniﬁed and pro-
longed compared with healthy volunteers (Sarkar et al., 2000).
Another possible example is the onset of IBS following GI infec-
tion (post-infectious IBS) where persistent sensitization of the
primary afferents due to for example increasedmast cells numbers,
T lymphocytes, and expression interleukin (IL)-1β (peripheral
sensitization), especially in the presence of risk factors such as
depression, hypochondriasis, and adverse life events (Spiller and
Garsed, 2009), could lead to central sensitization and the per-
sistence of symptoms, allodynia (pain to a stimulus that does not
normally provoke pain), hyperalgesia (increase in intensity of pain
to a stimulus that normally provokes pain), and dysmotility long
after the resolution of illness.
Thus there appears to be a dyssynergy between the interaction
of peripheral and central pain mechanisms, along with inﬂu-
ences from cognitive and emotional factors, and abnormalities
in descending inhibitory pathways that may all lead to the sen-
sation of abdominal pain and hypersensitivity in IBS. Central
mechanisms perhaps play a pivotal role integrating between these
processes and thus may represent a promising target for the devel-
opment of drugs for the treatment of IBS. For a more detailed
discussion of central, peripheral, and psychological processes in
IBS see the reviews Van Oudenhove and Aziz (2009), Knowles and
Aziz (2009), and Anand et al. (2007).
α2δ BINDING SITES
Gabapentin (Neurontin) was ﬁrst introduced as an antiepileptic
drug but has more recently been used in the treatment of posther-
petic neuralgia, diabetic neuropathy, migraine prophylaxis, and
chronic pain conditions (Taylor, 2009; Tzellos et al., 2010). Pre-
gabalin (Lyrica) is a second-generation compound structurally
related to gabapentin and approved in the US for the manage-
ment of neuropathic pain associated with diabetic peripheral neu-
ropathy, postherpetic neuralgia, ﬁbromyalgia, and as adjunctive
therapy for adults with partial onset seizures and for generalized
anxiety disorder (GAD). In Europe pregabalin is approved for
the treatment of neuropathic pain, epilepsy, and generalized anx-
iety disorder (Taylor, 2009; Tzellos et al., 2010). It has been, or
is being, assessed in many clinical trials for disorders such as IBS
and neuropathic pain in acute spinal cord injury (see US National
Institute of Health, www.ClinicalTrials.gov). Pregabalin has been
shown to be 2–10 times more potent than gabapentin and to pos-
sessmore linear pharmacokinetics (Ben-Menachem,2004;Huckle,
2004; Taylor, 2009; Tzellos et al., 2010).
Although structurally related to γ-aminobutyric acid (GABA),
a major inhibitory neurotransmitter in the CNS, gabapentin, and
pregabalin are functionally inactive at GABAA, GABAB, or ben-
zodiazepine receptors, and are not converted metabolically into
GABAor aGABA receptor agonist (Ben-Menachem,2004;Huckle,
2004; Taylor, 2009; Tzellos et al., 2010). In addition, clinically effec-
tive concentrations of gabapentin and pregabalin have been shown
to have no effect on GABA synthesis, uptake or degradation (Ben-
Menachem, 2004; Huckle, 2004; Field et al., 2006; Taylor, 2009;
Tzellos et al., 2010).
Both gabapentin and pregabalin bind with high afﬁnity to
α2δ subunits of voltage-gated calcium channels and this has been
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proposed as a likely site of their action. Further, inmicewithmuta-
tions of the α2δ subunits that prevent drug binding, pregabalin
and gabapentin are devoid of analgesic and anticonvulsant activity
(Field et al., 2006). Voltage-gated calcium channels are ubiquitous
in the body and are made up of an α1 subunit, which makes up
the ion-conducting pore, coupled together with other subunits
including β, γ, and α2δ. There is great heterogeneity within the
family of α1 subunits, of which 10 members have been described
in mammals (for review; Catterall et al., 2005). The α2δ subunit
appears to play a role not only in the operational characteristics
of individual channels, but also to enhance trafﬁcking of the α1
subunits to the cell membrane, so inﬂuencing the number of func-
tional calcium channels (Hendrich et al., 2008; Mich and Horne,
2008). Theα2δ subunit exists as fourdistinct subtypes and these are
encoded by four distinct genes (Klugbauer et al., 1999; Qin et al.,
2002). Only subtypes 1 and 2 have been shown to exhibit binding
for gabapentin and pregabalin and therefore might be expected to
underwrite the analgesic, anticonvulsant, and anxiolytic activity
of these drugs (Gong et al., 2001; Qin et al., 2002).
Despite the widespread localization of voltage-gated calcium
channels, the focus of studies to map the distribution of the α2δ
subunit has largely been restricted to tissues of the central ner-
vous system, with few studies exploring the potential for wider
distribution. At both the mRNA and protein level, α2δ-subtype 1
is widely distributed throughout human brain (Gong et al., 2001).
This widespread distribution of mRNA for the α2δ-subtype 1 has
been conﬁrmed in the central nervous system of the rat and was
reported in regions of the CNS involved in cortical processing,
learning and memory, defensive behavior, neuroendocrine secre-
tion, autonomic activation, primary sensory transmission, and
general arousal (Cole et al., 2005). These observations have been
conﬁrmed at the protein level using immunostaining with an anti-
body speciﬁc for α2δ-subtype 1 (Taylor and Garrido, 2008). In this
study, the most prominently stained regions of the CNS included
those areas involved in pain signaling, including the amygdala,
entorhinal cortex,hippocampus,ACC,and insula (Taylor andGar-
rido, 2008). In addition, a population of small diameter peripheral
sensory neurones in the dorsal root ganglia, together with their
projections to the spinal cord, stained prominently (Taylor and
Garrido, 2008). Immunostaining in the GI tract was also investi-
gated, although only data from the small intestine was reported
showing moderate staining in the smooth muscle (Taylor and
Garrido, 2008). To date, there has been only one report of neu-
ronal α2δ subunit expression in the intestine. In the guinea-pig,
in situ hybridization has revealed the α2δ-subtype 1 localized on
the intrinsic primary afferent neurones of the intestine, where
they appear to be associated with N-type calcium channels (Need-
ham et al., 2010). In these neurones, pregabalin had inhibitory
effects on both the action potential and the after hyperpolariza-
tion, raising the possibility that pregabalin may be able to reduce
the excitability of these sensory neurones and so potentially inhibit
GI hypersensitivity by an effect at these sites. The distribution of
α2δ-subtype 2 has been less extensively characterized. However,
in the rat, mRNA encoding α2δ-subtype 2 has been shown to be
widely distributed within the CNS, with particularly dense stain-
ing in the brainstem, the periaqueductal gray matter, the spinal
cord, and dorsal root ganglia (Cole et al., 2005). These are regions
known to play an important role in autonomic function and pain
processing. In tissues from human, mRNA for α2δ-subtype 2 was
detected in several brain regions but not in colon or small intes-
tine (Gong et al., 2001). The absence of α2δ-subtype 2 in human
jejunum was also conﬁrmed at the protein level.
The functional consequences of the binding of gabapentin/
pregabalin with the α2δ protein remain controversial. Data from
recombinant systems suggests that the function of the α2δ sub-
unit is heavily dependent on the subtype of α1 protein with
which the α2δ subunit is co-expressed and the cell system into
which the proteins are engineered. However, it is widely accepted
that the mechanism of action of these agents involves a modula-
tion of calcium conductance, but the precise mechanism for this
remains to be elucidated. The modulation of calcium currents
by gabapentin has been demonstrated in several studies of iso-
lated neurones (Stefani et al., 1998; Sutton et al., 2002; van Hooft
et al., 2002), although other studies have struggled to demon-
strate such an effect (Schlicker et al., 1985). More recently, it has
been proposed that gabapentin may exert an action through bind-
ing to the α2δ subunit within the cytosol, rather than at the cell
surface, and that this interaction can over time reduce the traf-
ﬁcking of α1/α2δ complexes to functional sites within the cell
membrane (Hendrich et al., 2008; Mich and Horne, 2008). Thus
gabapentin andpregabalinmay exert a range of effects, either acute
or chronic, mediated through diverse mechanisms, to modulate
calcium ﬂux in nerve terminals. The consequences of this disrup-
tion of calcium-mediated membrane depolarization have been
investigated extensively. Both gabapentin and pregabalin have
been shown to inhibit the release of a wide range of neurotrans-
mitters including noradrenaline, dopamine, 5-HT, acetylcholine,
glutamate, substance P, and CGRP from isolated slices of brain
and spinal cord from several species following stimulation with
either potassium or capsaicin (Dooley et al., 2000; Patel et al.,
2000; Fehrenbacher et al., 2003; Brawek et al., 2008). However, the
inhibitory effect of gabapentin and pregabalin may be stimulus-
dependant, as illustrated in the neocortex, where the magnitude of
inhibition of the release of noradrenaline was reduced when neu-
rotransmitter release was evoked by electrical stimulation rather
than potassium (Dooley et al., 2000). It has been suggested that
α2δ ligands may only exert their inhibitory effects on neuro-
transmitter release in “sensitized” situations and may exert only
limited effects in situations of normal physiology. For example,
in the spinal cord, gabapentin was only able to exert its presy-
naptic inhibitory inﬂuence on postsynaptic currents in animals
in which experimental diabetic neuropathy had been established
with streptozotocin and not in unsensitized animals (Patel et al.,
2000). Similarly, the pregabalin-mediated reductions in substance
P and CGRP release in the spinal cord of the rat are manifest only
in animals in which inﬂammation had been induced following
pre-treatment with intraplantar Freund’s adjuvant and are absent
in untreated animals (Fehrenbacher et al., 2003).
More recently, an additionalmechanismof action has been sug-
gested for gabapentin and pregabalin. In cell or neuronal cultures
gabapentin and pregabalin were shown to inhibit the activation of
the transcription factor NF-κB evoked by substance P (Park et al.,
2008). If conﬁrmed in additional studies, these observationsmight
help explain the increased efﬁcacy of gabapentin and pregabalin
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in circumstances of prior inﬂammation or sensitization, which
might be expected to lead to up-regulation of the NF-κB signaling
pathway.
PRE-CLINICAL MODELS OF NON-GI NEUROPATHIC PAIN
The anti-allodynic and anti-hyperalgesic properties of gabapentin
and pregabalin have been established in a wide range of ani-
mal models and the literature is too extensive to review here. In
summary, both of these α2δ ligands have been shown to mani-
fest these properties in animal models of inﬂammatory, surgical,
and neuropathic pain, including the inhibition of both the static
and dynamic components of allodynia (for example; Field et al.,
1997a,b, 1999). Interestingly, in a study of both sympathetically-
maintained and sympathetically-independent neuropathic pain,
pregabalin was particularly potent at inhibiting both tactile and
cold allodynia when given by the intrathecal route, suggesting
a predominantly spinal site of action, although the involvement
of supraspinal centers cannot be ruled out (Han et al., 2007).
Pregabalin was unable to inhibit cold allodynia in the model of
sympathetically-independent neuropathic pain when given via the
intraperitoneal route (Han et al., 2007). Experiments involving
direct recording from spinal neurons have demonstrated the abil-
ity of pregabalin to inhibit the C-ﬁber mediated response of spinal
nociceptive-speciﬁc neurons,without any effect on the responsive-
ness of A-δ ﬁbers (You et al., 2009). Further, pregabalin was also
able to inhibit central sensitization of the spinal neurons induced
by application of bee venom. Spinal transection conﬁrmed that the
effect of pregabalin in this study was likely to involve supraspinal
centers, mediated through descending inhibitory controls (You
et al., 2009).
PRE-CLINICAL MODELS OF GI SENSATION AND MOTILITY
Following the demonstration of the efﬁcacy of gabapentin and
pregabalin in animal models of neuropathic pain, investigations
of the proﬁle of these agents in small animalmodels of visceral pain
followed. Initial focus was on understanding whether gabapentin
and pregabalin might have utility in the treatment of IBS and so
studies focused on models of rectal or colonic hypersensitivity.
Caution needs to be applied when interpreting these data given
the recent history of notable failure of these models to predict the
effects of other new drugs on human pain and discomfort (e.g.,
those acting at neurokinin-1, NK1, or corticotrophin releasing
factor-1, CRF1, receptors). Despite this in the rat, the intraperi-
toneal administration of lipopolysaccharide (LPS) results, some
9–12 h later, in hypersensitivity of the rectum. The hypersensitiv-
ity can be demonstrated following rectal distension with a small
balloon and is manifest as both allodynia as well as hyperalgesia.
In this model, pregabalin, following either oral or intraperitoneal
administration, suppressed the rectal hypersensitivity response to
LPS (Eutamene et al., 2000). Pregabalin (1–30mg/kg p.o.) dose-
dependently inhibited the allodynia observed following distension
with the lowest volumeof 0.4mL.However,only the 10mg/kgdose
was able to reduce the nociceptive effect of the larger volumes
of distension. These observations were then extended in a more
chronic model of colonic allodynia (Diop et al., 2002). Seven days
after the administration of trinitrobenzene sulfonic acid (TNBS)
into the proximal colon of the rat, an allodynia to distension
was demonstrated in the distal colon of the animal. Histologi-
cal analysis revealed an inﬂammatory response in the proximal
colon, characterized by the presence of inﬂammatory cells, necro-
sis, and hyperemia, 3 days after dosing with TNBS. This response
had substantially diminished by day 7 and in the distal colon, no
increase in inﬂammatory cells was observed at any time point.
Hyperemia appeared to persist to day 7, the study day for these
experiments. Pregabalin (30–200mg/kg s.c.), given 30min prior
to the balloon distension of the distal colon, dose-dependently
reversed the allodynia observed 7 days after TNBS administra-
tion. Similar effects were seen following oral administration, 1 h
prior to balloondistension. In control animals not pre-treatedwith
TNBS, the highest dose of pregabalin (200mg/kg s.c.), which fully
reversed TNBS-induced allodynia, had no effect on colonic pain
thresholds, in contrast to morphine (0.3 and 1.0mg/kg) which
signiﬁcantly raised thresholds (Diop et al., 2002). In this model,
the inﬂammatory stimulus in the proximal colon establishes a sec-
ondary hyperalgesia and allodynia in the distal colon, presumably
through central sensitization at the level of the lumbar spinal cord,
although possibly also involving higher centers. These central ner-
vous system structures are the likely site of action of pregabalin in
this model and in the absence of sensitization, pregabalin had no
effect on sensation.
A series of studies with the prototype α2δ ligand gabapentin,
conﬁrmed that the effects on visceral pain were shared across
the class and not restricted to pregabalin. In both mice and rats,
gabapentin was shown to reduce the response evoked by intraperi-
toneal administration of acetic acid, a model of acute visceral
pain.Gabapentin (50–200mg/kg i.p.),dose-dependently inhibited
the number of abdominal contractions evoked by intraperitoneal
acetic acid when given 40min ahead of the stimulus (Feng et al.,
2003). The maximum effect was seen at 200mg/kg and inhib-
ited the abdominal response by approximately 75%. This dose
of gabapentin impaired the performance of rats on the beam-
balance test, suggestive of sedation, which can interfere with the
interpretation of tests of analgesia, raising the possibility that the
antinociceptive effect of gabapentin was secondary to sedative
effects. In this study, the investigators also attempted to develop
some mechanistic understanding of these observations and mea-
sured acute changes (over a 90-min observation) in the intrathecal
levels of several amino acids. Intraperitoneal administration of
acetic acid evoked large rises in both aspartate and glutamate.
These increases were inhibited completely by prior administra-
tion of gabapentin (100mg/kg i.p.). In addition, acetic acid also
increased the intrathecal levels of the inhibitory amino acid serine,
an increase that was also inhibited by gabapentin pre-treatment.
Intrathecal levels of the inhibitory amino acid, glycinewas reduced
to below baseline levels by gabapentin. In a broadly similar study,
this time conducted in mice, Stepanovic-Petrovic et al. (2008)
conﬁrmed the activity of gabapentin to inhibit the nocicep-
tive effects of peritoneal irritation evoked by acetic acid. In this
study, intraperitoneal administration evoked a writhing response,
characterized by abdominal contractions coupled with elonga-
tion of the body and extension of the hindlimbs. Intraperitoneal
administration of gabapentin (10–70mg/kg), 1 h before the acetic
acid, dose-dependently inhibited the writhing response. Once
again, this group compared the potency of gabapentin to inhibit
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acetic-acid-inducedwrithingwith its ability to impairmotor func-
tion, assessed using the rotarod test (a test of performance in
which the rodent is placed on a suspended horizontal rotating
rod [not high enough to injure the animal but high enough that
the animal avoids falling off] to measure balance, coordination
and motor planning). In this study, gabapentin was devoid of
activity in the rotarod test, even at doses of 2000mg/kg, thus
making it unlikely that the observed antinociceptive effects were
occurring secondary to sedation. In an interesting study fromMey-
mandi and Sepehri (2008), the antinociceptive effect of gabapentin
(1–100mg/kg i.p.) was conﬁrmed in the acetic acid-induced
writhing model. In the same study, the dose-response curve to
morphine was also constructed and then a low effective dose of
gabapentin was given as a combination with a sub-therapeutic
dose (0.25mg/kg i.p.) of morphine. This combination produced a
synergistic effect, as writhing was inhibited by over 90% compared
to control levels. Similarly, when the sub-therapeutic dose of mor-
phine was combined with a sub-therapeutic dose of gabapentin
(10mg/kg i.p.), a synergistic response was observed, with writhing
inhibited by approximately 70%. Interestingly, these synergistic
effects were not inhibited by treatment with naloxone. Simi-
lar observations, of a synergistic interaction between gabapentin
and morphine in models of visceral pain have been made pre-
viously in a rat model of experimental pancreatitis induced by
bradykinin infusion into the pancreas (Smiley et al., 2004). In
this model, gabapentin (100–300 μg intrathecally) only modestly
inhibited the behavioral response to bradykinin. However, when
the 300μg intrathecal dose of gabapentin was combined with
low intrathecal doses of morphine, shown previously to have
modest if any inhibitory effects in this model, signiﬁcant inhi-
bition of all aspects of the behavioral response to bradykinin
was observed. These observations taken together illustrate the
inhibitory effect of gabapentin on visceral pain, strongly sup-
port the concept that this effect is not underwritten or con-
founded by inhibiting arousal and point to potential synergy
with other antinociceptive mechanisms. These data also provide
in vivo evidence to support the hypothesis that gabapentin reduces
the release of excitatory and inhibitory neurotransmitters in the
spinal cord.
Recently, a study has been published comparing the effect of
pregabalin in the TNBS model of acute hypersensitivity with
a model of acute hypersensitivity induced by restraint stress
(Ohashi-Doi et al., 2010). As one might predict from previous
data, pregabalin (10–100mg/kg p.o.) reduced colonic nocicep-
tive thresholds dose-dependently in animals sensitized previously
with TNBS. In the stress restraint model, increased fecal output
in terms of number of pellets and fecal weight was observed dur-
ing the period of restraint stress. Pregabalin, over the same dose
range as examined in the TNBS model, also dose-dependently
inhibited the stress-induced increases in fecal output, but had no
effect on naive, unstressed rats. This is the only demonstration
to date that pregabalin can modulate stress-induced defecation in
rats. A comparison of the effects in the two models suggests that
pregabalin may be more potent at inhibiting the stress-induced
increases in defecation than at inhibiting TNBS-induced colonic
hypersensitivity.
The majority of studies of the effects of α2δ ligands on vis-
ceral pain have been restricted to acute models and largely to
those evoked by chemical irritants or pro-inﬂammatory stimuli.
More recently investigators have studied the effects of gabapentin
and pregabalin in models where less invasive and possibly more
physiologically relevant stimuli have been used to evoke an
acute or chronic phenotype. In a rat model, where repeated
tonic colorectal distension induces hypersensitivity, oral prega-
balin (10 and 30mg/kg) inhibited the development of hyperalgesia
(Million et al., 2007). Moreover, using Fos staining to indicate
neuronal activation, a single oral dose of pregabalin (30mg/kg)
blunted the activation of lumbosacral spinal neurones. These data
raise the possibility that in this model, pregabalin inhibits spinal
sensitization and so inhibits the development of hyperalgesia. It
has been demonstrated thatmaternal separation of rats in the early
neonatal period, a presumably highly stressful stimulus, can give
rise to hyperalgesia, revealed by colorectal distension, that is sus-
tained for many weeks after the original stress (Coutinho et al.,
2002) In an elegant study, to date only published as an abstract,
Coelho et al. (2008) conﬁrmed that a dose of gabapentin (30mg/kg
s.c.) that inhibited acute visceral pain evoked by intraperitoneal
acetic acid, was also able to inhibit the pain behaviors evoked
by colorectal distension in rats that had undergone maternal
separation 9–11weeks earlier.
New α2δ ligands are starting to appear in literature, but to date,
only one of these, PD-217014, which has similar binding afﬁn-
ity at the α2δ binding site as pregabalin, has been investigated
in an animal model of visceral hypersensitivity (Ohashi et al.,
2008). In the TNBS model described previously, oral dosing of
PD-217014 (3–100mg/kg) dose-dependently inhibited the reduc-
tion in colonic nociception threshold observed 7 days after TNBS
administration.Maximum inhibitionwas reached at 60mg/kg and
the inhibition at this dose was long lasting, reaching a peak at
2 h post-dose and lasting for between 6 and 8 h. Pharmacoki-
netic/pharmacodynamic (PK/PD) analysis clearly demonstrated
that maximum anti-hyperalgesia coincided with peak plasma
exposures. Interestingly, whilst the anti-hyperalgesic effect per-
sisted at 6 h post-dose, plasma levels had at this time dimin-
ished to low levels. These observations suggest that the persis-
tence of the pharmacological effect of PD-217014 is not simply
related to plasma exposure and this phenomenon requires further
investigation.
In a recent study, Ravnefjord et al. (2008) demonstrated in
normal, unsensitized rats that pregabalin (10–200 μmol/kg p.o.)
inhibited the viscerosomatic response to phasic, noxious colorec-
tal distension at 80mmHg as well as the viscerosomatic response
to ascending (10–80mmHg), phasic distension . In this study, the
highest dose of 200μmol/kg p.o. also inhibited the increases in
cardiovascular parameters (blood pressure and heart rate) seen
in response to noxious distension at 80mmHg. However, one
of the most interesting observations in this study, and one that
reveals another potential mechanism of action of pregabalin to
reduce pain thresholds in these distensionmodels,was an apparent
leftward shift in the colonic pressure-volume relationship. These
observations suggest that pregabalin may increase the compliance
of the colon in response to distension and by this mechanism
could effectively reduce the intensity of the nociceptive stimulus.
Similarly, this could be a mechanistic explanation for the obser-
vations of antinociceptive activity in models employing colorectal
distension as a nociceptive stimulus.
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CLINICAL EVIDENCE AND POTENTIAL UTILITY IN IBS
To date only two clinical studies have been published (Lee et al.,
2005; Houghton et al., 2007) assessing the effect of these com-
pounds on visceral sensitivity in IBS and one abstract in healthy
volunteers (Chua et al., 2009). No results from clinical trials exam-
ining the efﬁcacy of α2δ ligands on symptoms in IBS patients
have yet appeared in literature. However, there is one investigator-
sponsored small placebo-controlled trial of pregabalin in IBS
(NCT00977197), another investigator sponsored study looking
at the effect of pregabalin on colonic sensorimotor function in
healthy volunteers (NCT01094808) and a company-sponsored
clinical trial assessing the effect of the new generation α2δ lig-
and, PD-217014 in IBS (NCT00139672) currently listed on the US
National Institute of Health ClinicalTrial.gov website.
The ﬁrst study published assessed the effect of gabapentin
(300mg/day for the ﬁrst 3 days and the 600mg/day for the sub-
sequent 2 days) on rectal sensitivity to balloon distension in IBS
patients with diarrhea diagnosed using Rome II (IBS-D; Lee et al.,
2005). The authors reported that the threshold pressures for bloat-
ing, discomfort and pain, and rectal compliance all signiﬁcantly
increased after gabapentin but not following placebo. The increase
in rectal tone seen after meal ingestion was unaffected. Unfortu-
nately however, no direct comparison was made with placebo in
this study, so the signiﬁcance of their gabapentin ﬁndings needs
to be viewed with caution. The second study published by the
authors assessed the effect of pregabalin (titrated from 50mg tid
to 200mg tid over 3weeks) in IBS patients who exhibited rec-
tal hypersensitivity to mechanical distension (Houghton et al.,
2007). In comparison to placebo, pregabalin was shown to sig-
niﬁcantly increase or normalize the sensory thresholds for pain
(anti-allodynic effect), alongwith ﬁrst sensation anddesire to defe-
cate (anti-hyperalgesic effect), without desensitizing (i.e., make
hyposensitive) the perception of distension. If conﬁrmed by larger
studies and the results from the study currently in progress assess-
ing the effect of pregabalin on colonic sensorimotor function in
healthy volunteers (NCT01094808) proves to be negative, then
this would suggest that as shown in the animal models, desensiti-
zation only occurs in the presence of an hypersensitive state. Such
a compound would be most desirable for treatment of IBS and
conﬁrms studies in healthy volunteers showing that gabapentin
reduces signs of central sensitization induced by intradermal cap-
saicin (i.e., the area of brush and pinprick hyperalgesia) but not
spontaneous or evoked pain induced by capsaicin (Gottrup et al.,
2004). Similarly, a more recent study only published in abstract
form to date, showed that pregabalin prevents the development
of secondary hyperalgesia in the proximal esophagus after dis-
tal esophageal acidiﬁcation but had no effect on the primary
hyperalgesia induced in the distal esophagus (Chua et al., 2009),
supporting a central mode of action for pregabalin in reduction
of pain.
In addition to pregabalin’s effect on visceral sensation, and as
with the gabapentin rectal motor–sensory study (Lee et al., 2005)
and in the animalmodels (Ravnefjord et al., 2008) described previ-
ously, rectal compliance increased following pregabalin, although
there appeared to be no association with the observed reduction
in visceral pain (Houghton et al., 2007). This suggests additional
mechanisms of action, as yet to be explored. Similar observations
have been seen before with both clonidine and nitroglycerine both
increasing gastric compliance but only clonidine reducing pain
perception (Thumshirn et al., 1999).
Generalized anxiety disorder, as with IBS, is a common dis-
order. Furthermore studies have shown that 32–58% of patients
with IBS meet the diagnostic criteria for GAD (Lydiard, 2001),
a condition which has recently been shown to improve following
treatment with pregabalin (Stein et al., 2009). As well as improving
overall anxiety levels in GAD patients, the study showed that treat-
ment with pregabalin also led to an improvement in GI symptoms
that very often coexist in these patients and similar to those seen in
functional GI disorders, such as IBS (Stein et al., 2009). This raises
the possibility that GI symptoms might improve as a consequence
of the treatment of anxiety by pregabalin. Neither the presence of
GAD nor levels of co-existing anxiety or depression were mea-
sured in the study of rectal hypersensitivity (Houghton et al.,
2007), but the observation that pregabalin increased the sensory
thresholds for ﬁrst sensation and the desire to defecate, sensations
not normally expected to be under signiﬁcant psychological inﬂu-
ence, might suggest that the anxiolytic properties of pregabalin
were not playing a major role in modulating visceral sensation. In
support of this hypothesis, other studies using anxiolytic agents,
such as buspirone or antidepressants such as amitryptyline have
shown no effect on colonic sensitivity to balloon distension (Mertz
et al., 1998; Chial et al., 2003; Morgan et al., 2005). However, these
observations do not exclude the possibility an anxiolytic effect for
pregabalin in amelioration of IBS symptoms, especially in patients
with anxiety-induced increased defecation (as implicated by the
acute restraint stress animal model; Ohashi-Doi et al., 2010), but
clinical trials are required in which psychological symptoms along
with the cardinal IBS symptoms are measured to address the true
efﬁcacy of these agents in the treatment of IBS.
Other factors that might inﬂuence rectal sensation are the
adverse effects associatedwith pregabalin,namely dizziness and/or
somnolence. However, in the study of Houghton et al. (2007) these
side effects had resolved in themajority of patients by the time sen-
sitivity was assessed, and the change in sensory threshold in these
patients was no different from that seen in those still retaining
mild/moderate side effects, supporting data from animal studies
(Ohashi-Doi et al., 2010).
Furthermore the improvement in sensory threshold tended to
associate with a reduction in abdominal pain (Houghton et al.,
2007), supporting the observations that pregabalin improves GI
symptoms associated with GAD (Stein et al., 2009), and pain in
patients with ﬁbromyalgia (Hauser et al., 2009; Smith and Barkin,
2010; Straube et al., 2010). The results from the ongoing clini-
cal trials are eagerly awaited, and whether the patients have been
appropriately phenotyped to identify any sub-group improvement
based on their hypersensitivity or anxiety status also remains to be
revealed.
CONCLUSION
Gabapentin and pregabalin are valuable medicines being used
for the treatment of a number of conditions, including neuro-
pathic pain, epilepsy, anxiety, and ﬁbromyalgia.A body of evidence
implicates binding to the α2δ subunits of voltage-gated calcium
channels on presynaptic neuronal membranes as their most likely
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mechanism of action. However, recent data also points at poten-
tial additional mechanisms within the cell which may underwrite
some of their chronic effects and also indicates potential modula-
tion of pro-inﬂammatory pathways through inhibition of NF-κB
signaling. The modulation of calcium ﬂuxes evoked by gabapentin
and pregabalin has been shown to reduce the release of a broad
range of both excitatory and inhibitory neurotransmitters, pri-
marily in the central nervous system and hence this mechanism
has great potential to inﬂuence signaling pathways, including those
involved in pain transmission. Emerging data supports a role for
the α2δ subunit in neurotransmission in the enteric nervous sys-
tem, but the functional importance of these observations has yet
to be fully elucidated.
Data from animal models provides evidence for the inhibition
of both visceral nociception and GI function by gabapentin and
pregabalin in animals in which hypersensitivity has been induced
by either an inﬂammatory stimulus or stress, but largely illustrates
an absence of such activity on basal sensitivity or function.
When particularly strong noxious stimuli are used (acetic acid
or distension tohighpressures) effects on sensation inunsensitized
animals can be observed. These observations are in concordance
with earlier experiments performed using isolated in vitro prepa-
rations from animals in which hyperalgesia had been established.
The precise mechanism through which the α2δ ligands inhibit
intestinal allodynia and hyperalgesia has only been hinted at and
much remains as supposition. The extensive literature that indi-
cates the reduction in the release of neurotransmitters at the spinal
and supraspinal level by α2δ ligands remains a valid hypothesis
to explain the observations, with some supporting data obtained
from animal models of visceral pain.
The limited number of clinical studies of visceral pain per-
formed and reported to date support the observations in ani-
mals. In patients with IBS, both gabapentin and pregabalin
have been shown to reduce rectal sensitivity to balloon disten-
sion and in the study with pregabalin, anti-allodynia, and anti-
hyperalgesia was demonstrated in subjects with pre-characterized
rectal hypersensitivity. Data is expected soon from a similar
study in healthy volunteers which will illustrate whether these
agents have, like in many animal models, little effect on sen-
sory thresholds in subjects without hypersensitivity. Both ani-
mal and clinical data also suggest that α2δ ligands may alter
intestinal compliance and the signiﬁcance of this needs further
investigation. These data, supported by observations from animal
studies, support further investigation of α2δ ligands in disorders
characterized by visceral hypersensitivity such as IBS. Carefully
controlled, randomized clinical trials will be needed to fully under-
stand the potential of these agents to treat these bothersome
conditions.
REFERENCES
Agrawal, A., Houghton, L. A., Lea, R.,
Reilly, B., and Whorwell, P. J. (2008).
Abdominal bloating and distension
in irritable bowel syndrome: a role
for visceral sensation. Gastroenterol-
ogy 134, 1882–1889.
Almansa, C., Rey, E., Sanchez, G.,
Sanchez, A. A., and Diaz-Rubio, M.
(2009). Prevalence of functional gas-
trointestinal disorders in patients
with ﬁbromyalgia and the role of
psychologic distress. Clin. Gastroen-
terol. Hepatol. 7, 438–445.
Anand, P., Aziz, Q., Willert, R., and
Van Oudenhove, L. (2007). Periph-
eral and central mechanisms of vis-
ceral sensitization in man.Neurogas-
troenterol. Motil. 19, 29–46.
Ben-Menachem, E. (2004). Pregabalin
pharmacology and its relevance to
clinical practice. Epilepsia 45(Suppl.
6), 13–18.
Bouin, M., Plourde, V., Boivin, M.,
Riberdy, M., Lupien, F., Laganiere,
M.,Verrier, P., and Poitras, P. (2002).
Rectal distension testing in patients
with irritable bowel syndrome: sen-
sitivity, speciﬁcity, and predictive
values of pain sensory thresholds.
Gastroenterology 122, 1771–1777.
Brawek, B., Löfﬂer, M., Dooley, D. J.,
Weyerbrock, A., and Feuerstein, T.
J. (2008). Differential modulation
of K+-evoked 3H-neurotransmitter
release from human neocortex by
gabapentin and pregabalin. Naunyn
Schmiedebergs Arch. Pharmacol. 376,
301–307.
Catterall, W. A., Perez-Reyes, E.,
Snutch, T. P., and Striessnig, J.
(2005). InternationalUnionof Phar-
macology. XLVIII. Nomenclature
and structure-function relationships
of voltage-gated calcium channels.
Pharmacol. Rev. 57, 411–425.
Chial, H. J., Camilleri, M., Ferber,
I., Delgado-Aros, S., Burton, D.,
McKinzie, S., and Zinsmeister, A.
R. (2003). Effects of venlafaxine,
buspirone and placebo on colonic
sensorimotor function in healthy
humans. Clin. Gastroenterol. Hepa-
tol. 1, 211–218.
Chitkara, D. K., van Tilburg, M. A.,
Blois-Martin, N., and Whitehead,
W. E. (2008). Early life risk factors
that contribute to irritable bowel
syndrome in adults: a systematic
review. Am. J. Gastroenterol. 103,
765–774.
Chua, Y. C., Ng, K. S., Jafari, J., Sharma,
A., Surguy, S., Yazaki, E., Julu, P.
O., Knowles, C. H., and Aziz, Q.
(2009). Pregabalin prevents devel-
opment of esophageal hypersensi-
tivity to esophageal acid infusion in
healthy volunteers. Gastroenterology
138(Suppl. 1), 933; Abstract.
Coelho, A. M., O’Mahony, S., Tay-
lor, C., Wheeldon, A., Fitzgerald,
P., Dinan, T. G., Cryan, J. F.,
Lee, K., and Winchester, W. J.
(2008). Gabapentin reverses col-
orectal distension-induced visceral
pain behaviours in rat models of
acute and chronic visceral hypersen-
sitivity. Gastroenterology 134, A573.
Cofﬁn, B., Bouhassira, D., Sabate, J.-
M., Barbe, L., and Jian, R. (2004).
Alteration of the spinal modulation
of nociceptive processing in patients
with irritable bowel syndrome. Gut
53, 1465–1470.
Cole, R. L., Lechner, S. M., Williams,
M. E., Prodanovich, P., Bleicher,
L., Varney, M. A., and Gu, G.
(2005). Differential distribution
of voltage-gated calcium channel
alpha-2 delta (α2δ) subunit mRNA-
containing cells in the rat central
nervous system and the dorsal
root ganglia. J. Comp. Neurol. 491,
246–269.
Coutinho, S. V., Plotsky, P. M., Sablad,
M., Miller, J. C., Zhou, H., Bay-
ati, A. I., McRoberts, J. A., and
Mayer, E. A. (2002). Neonatal mater-
nal separation alters stress-induced
responses to viscerosomatic noci-
ceptive stimuli in rat. Am. J. Phys-
iol. Gastrointest. Liver Physiol. 282,
G307–G316.
Diop, L., Raymond, F., Fargeau, H.,
Petoux, F., Chovet, M., and Doherty,
A. M. (2002). Pregabalin (CI-1008)
inhibits the trinitrobenzene sulfonic
acid-induced chronic colonic allo-
dynia in the rat. J. Pharmacol. Exp.
Ther. 302, 1013–1022.
Dooley, D. J., Donovan, C. M.,
and Pugsley, T. A. (2000).
Stimulus-dependent modulation of
[3H]norepinephrine release from
rat neocortical slices by gabapentin
and pregabalin. J. Pharmacol. Exp.
Ther. 295, 1086–1093.
Eutamene, H., Coelho, A.-M.,
Theodorou, V., Toulouse, M.,
Chovet, M., Doherty, A., Fiora-
monti, J., and Bueno, L. (2000).
Antinociceptive effect of prega-
balin in septic shock-induced
rectal hypersensitivity in rats. J.
Pharmacol. Exp. Ther. 295, 162–167.
Fehrenbacher, J. C., Taylor, C. P., and
Vasko, M. R. (2003). Pregabalin and
gabapentin reduce release of sub-
stance P and CGRP from rat spinal
tissues only after inﬂammation or
activation of protein kinase C. Pain
105, 133–141.
Feng, Y., Cui, M., and Willis, W.
D. (2003). Gabapentin markedly
reduces acetic acid-induced vis-
ceral nociception. Anesthesiology 98,
729–733.
Field, M. J., Cox, P. J., Stott, E.,
Melrose, H., Offord, J., Su, T. Z.,
Bramwell, S., Corradini, L., England,
S., Winks, J., Kinloch, R. A., Hen-
drich, J., Dolphin, A. C., Webb, T.,
and Williams, D. (2006). Identiﬁca-
tion of the alpha2-delta-1 subunit of
voltage-dependent calcium channels
as a molecular target for pain medi-
ating the analgesic actions of pre-
gabalin. Proc. Natl. Acad. Sci. U.S.A.
103, 17537–17542.
Field, M. J., Oles, R. J., Lewis, A. S.,
McCleary, S., Hughes, J., and Singh,
L. (1997a). Gabapentin (neurontin)
and S-(+)-3-isobutylgaba represent
a novel class of selective antihyper-
algesic agents. Br. J. Pharmacol. 121,
1513–1522.
www.frontiersin.org June 2011 | Volume 2 | Article 28 | 7
Gale and Houghton α2δ Ligands and irritable bowel syndrome
Field, M. J., Holloman, E. F., McCleary,
S., Hughes, J., and Singh, L. (1997b).
Evaluation of gabapentin and S-
(+)-3-isobutylgaba in a rat model
of postoperative pain. J. Pharmacol.
Exp. Ther. 282, 1242–1246.
Field, M. S., McCleary, S., Hughes, J.,
and Singh, L. (1999). Gabapentin,
and Pregabalin but not morphine
and amitriptyline, block both
static and dynamic components of
mechanical allodynia induced by
streptozocin in the rat. Pain 80,
391–398.
Francis, C. Y., Houghton, L. A., Whor-
well, P. J., Morris, J., and Bradbury, J.
(1995). Enhanced sensitivity of the
whole gut in patients with irritable
bowel syndrome. Gastroenterology
108, 601.
Gong, H. C., Hang, J., Kohler, W., Li,
L., and Su, T. Z. (2001). Tissue-
speciﬁc expression and gabapentin-
binding properties of calcium chan-
nel alpha2delta subunit subtypes. J.
Membr. Biol. 184, 35–43.
Gottrup, H., Juhl, G., Kristensen, A.
D., Lai, R., Chizh, B. A., Brown, J.,
Bach, F. W., and Jensen, T. S. (2004).
Chronic oral gabapentin reduces ele-
ments of central sensitization in
human experimental hyperalgesia.
Anesthesiology 101, 1400–1408.
Hammonds, R. M., Houghton, L. A.,
Whorwell, P. J., Morris, J., Francis,
C. Y., and Mills, J. (1998). Whole gut
sensitivity in constipation predomi-
nant irritable bowel syndrome: 80%
of patients exhibit an abnormality.
Gastroenterology 114(Pt 2),G(3137).
Han, D. W., Kweon, T. D., Lee, J. S.,
and Lee, Y. W. (2007). Antiallodynic
effect of pregabalin in rat mod-
els of sympathetically maintained
and sympathetic independent neu-
ropathic pain. Yonsei Med. J. 48,
41–47.
Hauser, W., Bernardy, K., Uceyler, N.,
and Sommer, C. (2009). Treat-
ment of ﬁbromyalgia syndromewith
gabapentin and pregabalin – a meta-
analysis of randomized controlled
trials. Pain 145, 69–81.
Hendrich, J., Van Minh, A. T., Heblich,
F.,Nieto-Rostro,M.,Watschinger,K.,
Striessnig, J., Wratten, J., Davies, A.,
and Dolphin, A. C. (2008). Phar-
macological disruption of calcium
channel trafﬁcking by the α2δ lig-
and gabapentin.Proc.Natl. Acad. Sci.
U.S.A. 105, 3628–3633.
Heymen, S., Maixner, W., Whitehead,
W. E., Klatzkin, R. R., Mechlin, B.,
and Light, K. C. (2010). Central
processing of noxious somatic stim-
uli in patients with irritable bowel
syndrome compared with healthy
controls. Clin. J. Pain 26, 104–109.
Houghton, L. A., Fell, C., Whorwell, P.
J., Jones, I., Sudworth, D. P., and
Gale, J. D. (2007). Effect of second-
generation α2δ ligand (pregabalin)
on visceral sensation in hypersen-
sitive patients with irritable bowel
syndrome. Gut 56, 1218–1225.
Huckle, R. (2004). Pregabalin Pﬁzer.
Curr. Opin. Investig. Drugs 5, 82–89.
Klugbauer, N., Lacinová, L., Marais,
E., Hobom, M., and Hofmann, F.
(1999). Molecular diversity of the
calcium channel alpha2delta sub-
unit. J. Neurosci. 19, 684–691.
Knowles, C. H., and Aziz, Q. (2009).
Basic and clinical aspects of
gastrointestinal pain. Pain 141,
191–209.
Labus, J., Vianna, E. P. M., Tillisch, K.,
Naliboff, B., and Mayer, E. A. (2009).
Brain response during pelvic visceral
distension in healthy controls and
patients with irritable bowel syn-
drome. Neurogastroenterol. Motil.
21(Suppl. 1), 80; Abstract 267.
Lee, K. J., Kim, J. H., and Cho, S. W.
(2005). Gabapentin reduces rectal
mechanosensitivity and increases
rectal compliance in patients with
diarrhoea-predominant irrita-
ble bowel syndrome. Aliment.
Pharmacol. Ther. 22, 981–988.
Levy, R. L., Olden, K. W., Naliboff, B. D.,
Bradley,L.A.,Francisconi,C.,Dross-
man, D. A., and Creed, F. (2006).
Psychosocial aspects of functional
gastrointestinal disorders. Gastroen-
terology 130, 1447–1458.
Longstreth, F., Thompson, W. G., Chey,
W. D., Houghton, L. A., Mearin, F.,
and Spiller, R. (2006). Functional
bowel disorders. Rome III.Gastroen-
terology 130, 1480–1491.
Lydiard, R. B. (2001). Irritable bowel
syndrome, anxiety, and depression:
what are the links? J. Clin. Psychiatry
62(Suppl. 8), 38–45; Discussion 24.
Mayer, E. A., and Gebhart, G. F. (1994).
Basic and clinical aspects of visceral
hyperalgesia. Gastroenterology 107,
271–293.
Mertz, H., Fullerton, S., and Naliboff,
B. D. (1998). Symptoms and vis-
ceral perception in severe functional
and organic dyspepsia. Gut 42,
814–822.
Mertz, H., Naliboff, B., Munakata, J.,
Niazi, N., and Mayer, E. A. (1995).
Altered rectal perception is a biolog-
ical marker of patients with irrita-
ble bowel syndrome. Gastroenterol-
ogy 109, 40–52.
Meymandi, M.-S., and Sepehri, G.
(2008). Gabapentin action and
interaction on the antinociceptive
effect of morphine on visceral pain
in mice. Eur. J. Anaesthesiol. 25,
129–134.
Mich, P. M., and Horne, W. A. (2008).
Alternative splicing of the Ca2+
channel β4 subunit confers speci-
ﬁcity for gabapentin inhibition of
Cav2.1 trafﬁcking. Mol. Pharmacol.
74, 904–912.
Million, M., Wang, L., Adelson, D. W.,
Roman, F., Diop, L., and Taché,
Y. (2007). Pregabalin decreases vis-
ceral pain and prevents spinal neu-
ronal activation in rats. Gut 56,
1482–1484.
Morgan, V., Pickens, D., Gautam, S.,
Kessler, R., and Mertz, H. (2005).
Amitriptyline reduces rectal pain
related activation of the anterior
cingulated cortex in patients with
irritable bowel syndrome. Gut 54,
601–607.
Needham, K., Bron, R., Hunne, B.,
Nguyen, T. V., Turner, K., Nash,
M., and Furness, J. B. (2010). Iden-
tiﬁcation of subunits of voltage-
gated calcium channels and actions
of pregabalin on intrinsic primary
afferent neurons in the guinea-pig
ileum. Neurogastroenterol. Motil. 22,
e301–e308.
Ohashi, K., Kawai, ., Ninimiya, N., Tay-
lor, C., and Kurebayashi, Y. (2008).
Effect of a new α2δ ligand PD-
217014 on visceral hypersensitiv-
ity induced by 2,4,6-trinitrobenzene
sulfonic acid in rats. Pharmacology
81, 144–150.
Ohashi-Doi, K., Gale, J. D., and
Kurebayashi, Y. (2010). Pregabalin
inhibits accelerated defecation
and decreased colonic nociceptive
threshold in sensitized rats. Eur. J.
Pharmacol. 643, 107–112.
Park, S.,Ahn,E. S.,Han,D.W., Lee, J. H.,
Min, K. T., Kim, H., and Hong, Y. W.
(2008). Pregabalin and gabapentin
inhibit substance P-induced NF-
kappaB activation in neuroblastoma
and glioma cells. J. Cell. Biochem.
105, 414–423.
Patel, M. K., Gonzalez, M. I., Bramwell,
S., Pinnock, R. D., and Lee, K.
(2000). Gabapentin inhibits excita-
tory synaptic transmission in the
hyperalgesic spinal cord. Br. J. Phar-
macol. 130, 1731–1734.
Piche, M., Arsenault, M., Poitras,
P., Rainville, P., and Bouin, M.
(2010). Widespread hypersensitiv-
ity is related to altered pain inhi-
bition processes in irritable bowel
syndrome. Pain 148, 49–58.
Posserud, I., Syrous, A., Lindstrom, L.,
Tack, J., Abrahamsson, H., and Sim-
ren, M. (2007). Altered rectal per-
ception in irritable bowel syndrome
is associated with symptom severity.
Gastroenterology 133, 1113–1123.
Qin, N., Yagel, S., Momplaisir, M. L.,
Codd, E. E., and D’Andrea, M. R.
(2002). Molecular cloning and char-
acterization of the human voltage-
gated calcium channel α2δ-4 sub-
unit. Mol. Pharmacol. 62, 485–496.
Ravnefjord, A., Brusberg, M., Larsson,
H., Lindström, E., and Martínez,
V. (2008). Effects of pregabalin on
visceral pain responses and colonic
compliance in rats. Br. J. Pharmacol.
155, 407–416.
Saito, Y. A., and Talley, N. J. (2008).
Genetics of irritable bowel syn-
drome. Am. J. Gastroenterol. 103,
2100–2104.
Sarkar, S.,Aziz,Q.,Woolf, C. J.,Hobson,
A. R., and Thompson, D. G. (2000).
Contribution of central sensitization
to the development of non-cardiac
chest pain. Lancet 356, 1154–1159.
Schlicker, E., Reimann,W., and Göthert,
M. (1985). Gabapentin decreases
monoamine release without affect-
ing acetylcholine release in the
brain. Arzneimittelforschung 35,
1347–1349.
Seminowicz, D. A., Labus, J. S., Bueller,
J. A., Tillisch, K., Naliboff, B. D.,
Bushnell, M. C., and Mayer, E. A.
(2010). Regional gray matter density
changes in brains of patients with
irritable bowel syndrome. Gastroen-
terology 139, 48–57.
Smiley,M. M., Lu,Y.,Vera-Portocarrero,
L. P., Zidan, A., and Westlund, K.
N. (2004). Intrathecal gabapentin
enhances the analgesic effects of
subtherapeutic dose morphine in a
rat experimental pancreatitis model.
Anesthesiology 101, 759–765.
Smith, H. S., and Barkin, R. (2010).
Fibromyalgia syndrome: a discus-
sion of the syndrome and pharma-
cotherapy. Am. J. Ther. 17, 418–439.
Spiller, R., Aziz, Q., Creed, F.,
Emmanuel, A., Houghton, L.
A., Hungin, P., Jones, R., Kumar, D.,
Rubin, G., Trudgill, N., and Whor-
well, P. J. (2007). Guidelines on the
irritable bowel syndrome: mecha-
nisms and practical management.
Gut 56, 1770–1798.
Spiller, R., and Garsed, K. (2009).
Postinfectious irritable bowel
syndrome. Gastroenterology 136,
1979–1988.
Stefani, A., Spadoni, F., and Bernardi,
G. (1998). Gabapentin inhibits cal-
cium currents in isolated rat brain
neurons. Neuropharmacology 37,
83–91.
Stein, D. J., Bruce, L. R., Herman,
B. K., and Mandel, F. S. (2009).
Impact of gastrointestinal symp-
toms on response to pregabalin in
generalized anxiety disorder: results
of a six-study combined analy-
sis. Int. Clin. Psychopharmacol. 24,
126–132.
Frontiers in Pharmacology | Gastrointestinal Pharmacology June 2011 | Volume 2 | Article 28 | 8
Gale and Houghton α2δ Ligands and irritable bowel syndrome
Stepanovic-Petrovic, R. M., Tomic, M.
A., Vuckovic, S. M., Paranos, S.,
Ugresic, N. D., Prostran, M. S.,
Milovanovic, S., and Boskovic, B.
(2008). The antinociceptive effects
of anticonvulsants in a mouse vis-
ceral pain model. Anesth. Analg. 106,
1897–1903.
Straube, S., Derry, S., Moore, R.
A., Paine, J., and McQuay, H. J.
(2010). Pregabalin in ﬁbromyalgia –
responder analysis from individual
patient data. BMC Musculoskelet.
Disord. 11, 150. doi: 10.1186/1471-
2474-11-150.
Sutton, K. G., Martin, D. J., Pinnock,
R. D., Lee, K., and Scott, R. H.
(2002). Gabapentin inhibits high-
threshold calcium channel currents
in cultured rat dorsal root ganglion
neurones. Br. J. Pharmacol. 135,
257–265.
Taylor, C. P. (2009). Mechanisms of
analgesia by gabapentin and prega-
balin – calcium channel α2-δ [Cav
α2-δ] ligands. Pain 142; 13–16.
Taylor, C. P., and Garrido, R. (2008).
Immunostaining of rat brain, spinal
cord, sensory neurons and skeletal
muscle for calcium channel alpha2-
delta (α2-) type 1 protein. Neuro-
science 155, 510–521.
Thumshirn, M., Camilleri, M., Choi, M.
G., and Zinsmeister, A. R. (1999).
Modulation of gastric sensory and
motor functions by nitrergic and α2-
adrenergic agents in humans. Gas-
troenterology 116, 573–585.
Tzellos, T. G., Papazisis, G., Toulis, K.
A., Sardeli, C. H., and Kouvelas, D.
(2010). α2-δ ligands gabapentin and
pregabalin: future implications in
daily clinical practice. Hippokratia
14, 71–75.
van Hooft, J. A., Dougherty, J. J.,
Endeman, D., Nichols, R. A., and
Wadman, W. J. (2002). Gabapentin
inhibits presynaptic Ca2+ inﬂux and
synaptic transmission in rat hip-
pocampus and neocortex. Eur. J.
Pharmacol. 449, 221–228.
Van Oudenhove, L., andAziz,Q. (2009).
Recent insights on central pro-
cessing and psychological processes
in functional gastrointestinal disor-
ders. Dig. Liver Dis. 41, 781–787.
Verne, G. N., Robinson, M. E., and
Price, D. D. (2001). Hypersensitiv-
ity to visceral and cutaneous pain in
the irritable bowel syndrome. Pain
93, 7–14.
Whitehead,W. E.,Palsson,O., and Jones,
K. R. (2002). Systematic review of
the comorbidity of irritable bowel
syndromewith other disorders:what
are the causes and implications?Gas-
troenterology 122, 1140–1156.
Whitehead, W. E., and Palsson, O. S.
(1998). Is rectal pain sensitivity a
biological marker for irritable bowel
syndrome: psychological inﬂuences
on pain perception.Gastroenterology
115, 1263–1271.
Whorwell, P. J.,McCallum,M., Creed, F.
H., and Roberts, C. T. (1986). Non-
colonic features of irritable bowel
syndrome. Gut 27, 37–40.
You, H. J., Lei, J., and Arendt-Nielsen,
L. (2009). Selective inhibitory
effects of pregabalin on peripheral
C but not A-delta ﬁbers medi-
ated nociception in intact and
spinalized rats. Neuroscience 164,
1845–1853.
Conﬂict of Interest Statement: Dr.
Jeremy Gale is an employee and share-
holder of Pﬁzer. Professor Lesley A.
Houghton has served as a speaker,
a consultant, and/or an advisory
board member for Novartis, Pﬁzer,
Solvay Pharmaceuticals, GlaxoSmithK-
line, Clasado, Ono Pharma UK Ltd.,
Kelloggs UK, Norgine Ltd., and
Boehringer Ingelheim; the Neuro-
gastroenterology Unit, University of
Manchester/University Hospital of
South Manchester NHS Foundation
Trust, UK has received research funding
from Novartis, Pﬁzer, Solvay Phar-
maceuticals, GlaxoSmithKline, and
Danone Research; and the Division
of Gastroenterology and Hepatology,
Mayo Clinic, Jacksonville, USA has
received research funding from Edusa
Pharmaceuticals, Inc., USA.
Received: 08 February 2011; accepted:
29 May 2011; published online: 09 June
2011.
Citation: Gale JD and Houghton LA
(2011) Alpha 2 delta (α2δ) ligands,
gabapentin and pregabalin: what is
the evidence for potential use of
these ligands in irritable bowel syn-
drome. Front. Pharmacol. 2:28. doi:
10.3389/fphar.2011.00028
This article was submitted to Frontiers
in Gastrointestinal Pharmacology, a spe-
cialty of Frontiers in Pharmacology.
Copyright © 2011 Gale and Houghton.
This is an open-access article subject
to a non-exclusive license between the
authors and Frontiers Media SA, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and other
Frontiers conditions are complied with.
www.frontiersin.org June 2011 | Volume 2 | Article 28 | 9
